Intravenous pamidronate for hypercalcemia of primary hyperparathyroidism.

Intravenous pamidronate disodium has been used successfully in the treatment of malignancy-associated hypercalcemia and Paget's disease of bone. Although the definitive treatment of primary hyperparathyroidism (PHPT) is surgical, intravenous pamidronate has been used to treat hypercalcemia of PHPT when surgery was contraindicated. We report two cases of PHPT in which intravenous pamidronate effectively reduced hypercalcemia and significantly improved the clinical symptoms. The results of our study and the experience in the literature suggest that pamidronate is a safe and effective method of reducing serum calcium in patients with PHPT when definitive surgery is contraindicated or must be postponed.
AuthorsA Tal, L Graves
JournalSouthern medical journal (South Med J) Vol. 89 Issue 6 Pg. 637-40 (Jun 1996) ISSN: 0038-4348 [Print] UNITED STATES
PMID8638211 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Diphosphonates
  • Parathyroid Hormone
  • pamidronate
  • Calcium
  • Aged
  • Calcium (blood)
  • Diphosphonates (administration & dosage, therapeutic use)
  • Female
  • Humans
  • Hypercalcemia (blood, drug therapy, etiology)
  • Hyperparathyroidism (blood, complications)
  • Infusions, Intravenous
  • Male
  • Middle Aged
  • Parathyroid Hormone (blood)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: